Unassociated Document
As
filed with the Securities and Exchange Commission December 7,
2009
|
Registration
No. 333-
|
|
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
ZIOPHARM
Oncology, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
(State
or jurisdiction
of
incorporation or organization)
|
|
84-1475642
(I.R.S.
Employer
Identification
No.)
|
1180
Avenue of the Americas, 19th Floor
New
York, NY 10036
(646)
214-0700
(Address
and telephone number of registrant’s principal executive offices and
principal place of business)
|
Dr.
Jonathan Lewis
Chief
Executive Officer
ZIOPHARM
Oncology, Inc.
1180
Avenue of the Americas, 19th Floor
New
York, NY 10036
Telephone:
(646) 214-0700
Facsimile:
(646) 214-0711
(Name,
address and telephone number of agent for service)
|
|
Copies
to:
Alan
M. Gilbert, Esq.
Maslon
Edelman Borman & Brand, LLP
90
South 7th Street, Suite 3300
Minneapolis,
Minnesota 55402
Telephone:
(612) 672-8200
Facsimile:
(612)
642-8381
|
Approximate date of proposed sale to
the public: From time to time after the effective date of this
Registration Statement.
If the
only securities being registered on this form are being offered pursuant to
dividend or interest reinvestment plans, please check the following
box. ¨
If any of
the securities being registered on this form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other
than securities offered only in connection with dividend or interest
reinvestment plans, check the following box: þ
If this
form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. þ SEC File No.
333-161453
If this
form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. ¨
If this
form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with
the Commission pursuant to Rule 462(e) under the Securities Act, check the
following box. ¨
If this
form is a post-effective amendment to a registration statement filed pursuant to
General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the
Securities Act, check the following box. ¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definition of “large accelerated filer,” “accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act. (Check one):
Large
accelerated filer ¨
|
|
Accelerated
filer ¨
|
|
|
|
Non-accelerated
filer ¨
|
|
Smaller
reporting company þ
|
(Do not
check if a smaller reporting company)
CALCULATION
OF REGISTRATION FEE
|
|
Title Of Each Class Of
Securities To Be Registered
|
|
Amount To Be
Registered (1)(2)(3)(4)
|
|
|
Proposed Maximum
Aggregate
Offering Price (2)(3)(4)(5)
|
|
|
Amount Of
Registration Fee (6)
|
|
Common
stock, par value $.001 per share
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
Stock, par value $0.001 per share
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt
Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
5,989,525 |
|
|
$ |
5,989,525 |
|
|
$ |
334.22 |
|
|
(1)
|
In
accordance with Rule 462(b) promulgated under the Securities Act an
additional amount of securities having a proposed maximum aggregate
offering price of no more than 20% of the maximum aggregate offering price
of the securities eligible to be sold under the Registration Statement on
Form S-S (File No. 333-161453), as amended, is hereby
registered.
|
|
(2)
|
An indeterminate number of shares
of common stock and preferred stock, an indeterminate number of warrants
to purchase debt securities, common stock or preferred stock and an
indeterminate amount of debt securities are being registered hereunder,
but in no event will the aggregate initial offering price exceed
$75,000,000. If any debt securities are issued at an original issue
discount, then the offering price of such debt securities shall be in such
greater principal amount as shall result in an aggregate initial offering
price not to exceed $75,000,000, less the aggregate dollar amount of all
securities previously issued hereunder. Any securities registered
hereunder may be sold separately or as units with other securities
registered hereunder. The securities registered also include such
indeterminate amount and number of shares of common stock and preferred
stock as may be issued upon conversion of or exchange for preferred stock
and provide for conversion or exchange, upon exercise of warrants or
pursuant to antidilution provisions of any such securities. In
addition, pursuant to Rule 416 under the Securities Act, there are also
being registered hereunder an indeterminate number of shares of common
stock and preferred stock as may be issuable with respect to the shares
being registered hereunder as a result of stock splits, stock dividends or
similar transactions.
|
|
|
|
|
(3) |
Unspecified
pursuant to General Instruction II.D to Form S-3 under the Securities
Act. |
|
(4)
|
Represents
only the additional amount of securities being registered. Does not
include the securities that the Registrant previously registered on the
Registration Statement on Form S-3 (File No.
333-161453).
|
|
(5)
|
Estimated
solely for the purpose of calculating the registration fee pursuant to
Section 6(b) of the Securities Act and computed pursuant to Rule 457(o)
under the Securities Act and based upon the average of the high and low
sale prices for such stock on December 4, 2009, as reported by the NASDAQ
Capital Market.
|
|
(6)
|
Represents
the registration fee only for the additional number of shares being
registered. A filing fee of $4,185.00 was previously paid for the
securities that the Registrant previously registered on the Registration
Statement on Form S-3 (File No.
333-161453).
|
This
registration statement shall become effective upon filing with the Securities
and Exchange
Commission
in accordance with Rule 462(b) under the Securities Act of 1933, as
amended.
EXPLANATORY
NOTE AND
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
We are
filing this registration statement with the Securities and Exchange Commission
(the “Commission”) pursuant to Rule 462(b) under the Securities Act of 1933, as
amended. This registration statement relates to the public offering of
securities contemplated by the registration statement on Form S-3 (File
No. 333-161453), originally filed by us with the Commission on August 20,
2009, and subsequently amended, and includes the registration statement facing
page, this page, the signature page, an exhibit index and exhibits. It is being
filed for the sole purpose of registering an additional $5,989,525 of securities pursuant
to Rule 462(b), which amount does not represent more than 20% of the maximum
aggregate offering price set forth for the securities in the “Calculation of
Registration Fee” table in the registration statement on Form S-3 (File
No. 333-161453), as amended.
The
information in the registration statement on Form S-3 (File
No. 333-161453), as amended by Pre-Effective Amendment No. 1 thereto
filed with the Commission on September 14, 2009, is incorporated by reference
into this registration statement. The required opinions and consents are listed
on the exhibit index attached hereto and filed herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this Registration Statement on Form S-3
to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of New York, State of New York, on December 7, 2009.
ZIOPHARM
Oncology, Inc.
|
|
|
By:
|
/s/ Jonathan Lewis
|
|
Jonathan
Lewis
|
|
Chief
Executive Officer
|
POWER
OF ATTORNEY
Each person whose signature appears
below hereby constitutes and appoints Jonathan Lewis and Richard E. Bagley, and
each of them, as his true and lawful attorneys-in-fact and agents, with full
power of substitution and resubstitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this registration statement, and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents, full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorney-in-fact and agent or his substitutes or
substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Amendment No. 1 to the
registration statement has been signed by the following persons in the
capacities and on the dates indicated.
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Jonathan Lewis
|
|
Director
and Chief Executive Officer
|
|
December
7, 2009
|
Jonathan
Lewis
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/ Richard Bagley
|
|
Director,
President, Treasurer and Chief
|
|
December
7, 2009
|
Richard
E. Bagley
|
|
Operating
Officer (Principal Accounting and Financial Officer)
|
|
|
|
|
|
|
|
/s/ Murray Brennan
|
|
Director
|
|
December
7, 2009
|
Murray
Brennan
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December
7, 2009
|
James
Cannon
|
|
|
|
|
|
|
|
|
|
/s/ Timothy McInerney
|
|
Director
|
|
December
7, 2009
|
Timothy
McInerney
|
|
|
|
|
|
|
|
|
|
/s/ Wyche Fowler, Jr.
|
|
Director
|
|
December
7, 2009
|
Wyche
Fowler, Jr.
|
|
|
|
|
|
|
|
|
|
/s/ Gary S. Fragin
|
|
Director
|
|
December
7, 2009
|
Gary
S. Fragin
|
|
|
|
|
|
|
|
|
|
/s/ Michael Weiser
|
|
Director
|
|
December
7, 2009
|
Michael
Weiser
|
|
|
|
|
|
|
|
|
|
EXHIBIT
INDEX
Exhibit No.
|
|
Description of Document
|
|
|
|
5.1
|
|
Legal
opinion of Maslon Edelman Borman & Brand, LLP
|
23.1
|
|
Consent
of Independent Registered Public Accounting Firm - Caturano and Company,
P.C.
|
23.2
|
|
Consent
of Maslon Edelman Borman & Brand, LLP (included as part of Exhibit
5.1)
|
24.1
|
|
Power
of Attorney (included on signature
page)
|
Exhibit
5.1
December
7, 2009
ZIOPHARM
Oncology, Inc.
1180
Avenue of the Americas, 19th Floor
New York,
New York 10036
Re:
Registration Statement on Form S-3 (the “Registration
Statement”)
Ladies
and Gentlemen:
We have
served as counsel for to ZIOPHARM Oncology, Inc., a Delaware corporation (the
“Company”), in
connection with the Registration Statement on Form S-3, Registration no.
333-161453 (the “Registration
Statement”), filed with the Securities and Exchange Commission under the
Securities Act of 1933, as amended (the “Securities Act”), and the
additional Registration Statement on Form S-3 (the “Abbreviated Registration
Statement”) filed pursuant to Rule 462(b) under the Act. This
opinion is being furnished in accordance with the requirements of
Item 601(b)(5) of Regulation S-K under the Securities Act, and no
opinion is expressed herein as to any matter pertaining to the contents of the
Registration Statement, the Prospectus or any Prospectus Supplement (both as
herein defined) other than as to (i) the enforceability of the Agreements,
the Debt Securities and the Warrants (each as herein defined) and (ii) the
validity of the shares of the Common Stock and the Preferred Stock (both as
herein defined).
You have
provided us with the Registration Statement and a draft of the Abbreviated
Registration Statement in the form in which it will be filed, which include or
incorporate by reference the prospectus (the “Prospectus”). The Prospectus
provides that it will be supplemented in the future by one or more supplements
to the Prospectus (each, a “Prospectus Supplement”). The
Prospectus, as supplemented by various Prospectus Supplements, will provide for
the registration by the Company of (i) one or more series of debt
securities (the “Debt
Securities”), (ii) shares of preferred stock, par value $0.001 per
share (the “Preferred
Stock”), (iii) shares of common stock, par value $0.001 per share
(the “Common Stock”) and
(iv) warrants to purchase Common Stock, Preferred Stock or Debt Securities
(the “Warrants”), or any
combination of the foregoing (collectively, the “Securities”), for an aggregate
initial offering price of up to $80,989,525.00, which includes securities having
a maximum aggregate offering price of up to $75,000,000 covered by the
Registration Statement and securities having a maximum aggregate offering price
of up to $5,989,525 covered by
the Abbreviated Registration Statement. Any Debt Securities may be
exchangeable for and/or convertible into shares of Common Stock or Preferred
Stock or into other securities. The Preferred Stock may also be convertible into
shares of Common Stock or another series of Preferred Stock or into other
securities. The Debt Securities may be issued pursuant to an indenture by and
between the Company and a financial institution to be identified therein as
trustee (the “Trustee”)
in the form filed as Exhibit 4.8 to the Registration Statement, as such
indenture may be supplemented from time to time (the “Indenture”). The Warrants may
be issued under one or more warrants and warrant agreements in the
forms to be incorporated by reference as Exhibits 4.9 and 4.10 to the
Registration Statement (each, a “Warrant Agreement”) between
the Company and a bank or trust company to be identified therein as warrant
agent (each, a “Warrant
Agent”). The Indenture and the Warrant Agreements are herein collectively
called the “Agreements.”
For the
purposes of this opinion, we have assumed that such proceedings to be taken in
the future will be timely completed in the manner presently proposed and that
the terms of each issuance will otherwise be in compliance with law. As such
counsel, we have examined such matters of fact and questions of law as we have
considered appropriate for purposes of this letter. With your consent, we have
relied upon the foregoing and upon certificates and other assurances of officers
of the Company and others as to factual matters without having independently
verified such factual matters.
We are
opining herein as to the effect on the subject transaction only of the General
Corporation Law of the State of Delaware and we express no opinion with respect
to the applicability thereto, or the effect thereon, of the laws of any other
jurisdiction or, in the case of Delaware, any other laws, or as to any matters
of municipal law or the laws of any local agencies within any state. With
respect to our opinion in Paragraph 1 relating to the enforceability of the
Indenture , which the form of which is by its terms governed by the laws of the
State of New York, we have assumed without investigation or review that the
internal law of the State of New York is identical to the internal law of the
State of Delaware.
Subject
to the foregoing and the other matters set forth herein, it is our opinion that
as of the date hereof:
1. When
(i) the Indenture has been duly authorized, executed and delivered by the
Company and the Trustee, (ii) the Debt Securities have been duly authorized
and duly established in accordance with the Indenture and applicable law
(including, without limitation, by the adoption by the Board of Directors of the
Company of a resolution duly authorizing the issuance and delivery of the Debt
Securities) (the “Debt
Securities Authorization”), duly authenticated by the Trustee and duly
executed and delivered on behalf of the Company against payment therefor in
accordance with the terms and provisions of the Indenture and as contemplated by
the Registration Statement, the Prospectus and the related Prospectus
Supplement(s), and the Debt Securities Authorization, and assuming that
(a) the terms of the Debt Securities as executed and delivered are as
described in the Registration Statement, the Prospectus and the related
Prospectus Supplement(s), and the Debt Securities Authorization, (b) the
Debt Securities as executed and delivered do not violate any law applicable to
the Company or result in a default under or breach of any agreement or
instrument binding upon the Company, (c) the Debt Securities as executed and
delivered comply with all requirements and restrictions, if any, applicable to
the Company, whether imposed by any court or governmental or regulatory body
having jurisdiction over the Company or otherwise, and (d) the Debt
Securities are then issued and sold as contemplated in the Registration
Statement, the Prospectus and the related Prospectus Supplement(s), and the Debt
Securities Authorization, the Debt Securities (including any Debt Securities
duly issued (i) upon the exchange or conversion of any Debt Securities that
are exchangeable or convertible into another series of Debt Securities or
(ii) upon the exercise of any Warrants pursuant to the terms thereof that
are exercisable for the purchase of Debt Securities) will constitute legally
valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms.
2. When
(i) a form of certificate representing the shares of Preferred Stock has
been duly adopted by resolution of the Board of Directors and certificates in
such form have been executed, countersigned, registered and delivered,
(ii) a series of Preferred Stock has been duly established in accordance
with the terms of the Company’s certificate of incorporation (the “Certificate of
Incorporation”), and applicable law, and upon adoption by the Board of
Directors of the Company of a resolution in form and content as required by
applicable law authorizing the issuance of such shares and upon issuance and
delivery of and payment of legal consideration not less than the par value
thereof, and assuming that (a) the terms of such shares as issued and
delivered are as described in the Registration Statement, the Prospectus and the
related Prospectus Supplement(s), and such resolution, (b) at the time of
issuance of such shares, the Company has a sufficient number of authorized but
unissued shares under the Certificate of Incorporation, (c) such shares as
issued and delivered comply with all requirements and restrictions, if any,
applicable to the Company, whether imposed by any court or governmental or
regulatory body having jurisdiction over the Company or otherwise and
(d) such shares are then issued and sold as contemplated in the
Registration Statement, the Prospectus and the related Prospectus Supplement(s),
and such resolution, such shares of such series of Preferred Stock (including
any Preferred Stock duly issued (i) upon the exchange or conversion of any
shares of Preferred Stock that are exchangeable or convertible into another
series of Preferred Stock, (ii) upon the exercise of any Warrants pursuant
to the terms thereof that are exercisable for the purchase of Preferred Stock or
(iii) upon the exchange or conversion of Debt Securities that are
exchangeable or convertible into Preferred Stock) will be validly issued,
fully-paid and nonassessable.
3. Upon
adoption by the Board of Directors of the Company of a resolution in form and
content as required by applicable law authorizing the issuance of shares of
Common Stock and upon issuance and delivery of and payment of legal
consideration not less than the par value thereof for certificates representing
the shares of Common Stock in the form of the specimen certificate incorporated
by reference as Exhibit 4.5 to the Registration Statement being duly
executed, countersigned, registered and delivered, and assuming that (i) at
the time of issuance of such shares, the Company has a sufficient number of
authorized but unissued shares under the Certificate of Incorporation, (ii) such
shares as issued and delivered comply with all requirements and restrictions, if
any, applicable to the Company, whether imposed by any court or governmental or
regulatory body having jurisdiction over the Company or otherwise and
(iii) such shares are then issued and sold as contemplated in the
Registration Statement, the Prospectus, the related Prospectus Supplement(s) and
such resolution, such shares of Common Stock (including any Common Stock duly
issued (a) upon the exchange or conversion of any shares of Preferred Stock
that are exchangeable or convertible into Common Stock, (b) upon the
exercise of any Warrants pursuant to the terms thereof that are exercisable for
the purchase of Common Stock or (c) upon the exchange or conversion of Debt
Securities that are exchangeable or convertible into Common Stock) will be
validly issued, fully paid and nonassessable.
4. When
(i) the applicable Warrant Agreement has been duly authorized, executed and
delivered by the Company and the Warrant Agent, (ii) the Warrants have been
duly authorized and duly established in accordance with the terms of the Warrant
Agreement and applicable law (including, without limitation, by the adoption by
the Board of Directors of the Company of a resolution duly authorizing the
issuance and delivery of the Warrants) (the “Warrant Authorization”) and
(iii) the Warrants have been duly executed, authenticated and/or
countersigned in accordance with the Warrant Agreement relating to such Warrants
and delivered on behalf of the Company against payment therefor (which, in the
case of Warrants for Common Stock or Preferred Stock, shall consist of legal
consideration not less than the par value of such shares) as contemplated by the
Registration Statement, the Prospectus, the related Prospectus Supplement(s) and
the Warrant Authorization, and assuming that (a) the terms of the Warrants
as executed and delivered are as described in the Registration Statement, the
Prospectus, the related Prospectus Supplement(s) and the Warrant Authorization,
(b) the Warrants as executed and delivered do not violate any law
applicable to the Company or result in a default under or breach of any
agreement or instrument binding upon the Company, (c) the Warrants as
executed and delivered comply with all requirements and restrictions, if any,
applicable to the Company, whether imposed by any court or governmental or
regulatory body having jurisdiction over the Company or otherwise and
(d) the Warrants are then issued and sold as contemplated by the
Registration Statement, the Prospectus, the related Prospectus Supplement(s) and
the Warrant Authorization, the Warrant Agreement and the Warrants will
constitute legally valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms.
5. When
the Indenture has been duly authorized, executed and delivered by the Company
and the Trustee, and assuming that (i) the Indenture does not violate any
law applicable to the Company or result in a default under or breach of any
agreement or instrument binding upon the Company, and (ii) the Indenture
complies with all requirements and restrictions, if any, applicable to the
Company, whether imposed by any court or governmental or regulatory body having
jurisdiction over the Company or otherwise, the Indenture will constitute the
legally valid and binding obligation of the Company, enforceable against the
Company in accordance with its terms.
Our
opinions are subject to:
(i) the
effect of bankruptcy, insolvency, reorganization, preference, fraudulent
transfer, moratorium or other similar laws relating to or affecting the rights
and remedies of creditors; (ii) the effects of general principles of
equity, whether enforcement is considered in a proceeding in equity or at law
(including the possible unavailability of specific performance or injunctive
relief), concepts of materiality, reasonableness, good faith and fair dealing,
and the discretion of the court before which a proceeding is brought;
(iii) the invalidity under certain circumstances under law or court
decisions of provisions for the indemnification of or contribution to a party
with respect to a liability where such indemnification or contribution is
contrary to public policy; and (iv) we express no opinion with respect to
(a) consents to, or restrictions upon, governing law, jurisdiction, venue,
arbitration, remedies or judicial relief; (b) advance waivers of claims,
defenses, rights granted by law, or notice, opportunity for hearing, evidentiary
requirements, statutes of limitation, trial by jury or at law, or other
procedural rights; (c) waivers of broadly or vaguely stated rights;
(d) covenants not to compete; (e) provisions for exclusivity, election
or cumulation of rights or remedies; (f) provisions authorizing or
validating conclusive or discretionary determinations; (g) grants of setoff
rights; (h) provisions to the effect that a guarantor is liable as a
primary obligor, and not as a surety; (i) provisions for the payment of
attorneys’ fees where such payment is contrary to law or public policy;
(j) proxies, powers and trusts; (k) provisions prohibiting,
restricting, or requiring consent to assignment or transfer of any right or
property; (l) provisions for liquidated damages, default interest, late
charges, monetary penalties, make-whole premiums or other economic remedies to
the extent such provisions are deemed to constitute a penalty; and (m) the
severability, if invalid, of provisions to the foregoing effect.
In
addition, we express no opinion with respect to (i) whether acceleration of
the Debt Securities may affect the collectibility of that portion of the stated
principal amount thereof that might be determined to constitute unearned
interest thereon, (ii) compliance with laws relating to permissible rates
of interest, (iii) the creation, validity, perfection or priority of any
security interest, mortgage, or lien, or (iv) any provision to the extent
it requires any party to indemnify any other person against loss in obtaining
the currency due following a court judgment in another
currency.
We have
not been requested to express and, with your consent, do not render any opinion
as to the applicability to the obligations of the Company under the Indenture or
the Debt Securities of Sections 547 and 548 of the United States Bankruptcy
Code or applicable state law relating to preferences and fraudulent transfers
and obligations.
With your
consent, we have assumed for purposes of this opinion that (i) each of the
parties to the Agreements, the Debt Securities and the Warrants other than the
Company (a) is duly organized, validly existing and in good standing under
the laws of its jurisdiction of organization; (b) has the requisite power
and authority to execute and deliver and to perform its obligations under each
of the Agreements, the Debt Securities and the Warrants to which it is a party;
and (c) has duly authorized, executed and delivered each such Agreement,
Debt Security and Warrant; (ii) that the Agreements, the Debt Securities
and the Warrants will have been duly authorized, executed and delivered by, and
constitute legally valid and binding obligations of, the parties thereto and
will be, other than as to the Company, enforceable against it in accordance with
their respective terms; and (iii) that the status of the Agreements, the
Debt Securities and the Warrants as legally valid and binding obligations of the
respective parties thereto will not be affected by any (a) breaches of, or
defaults under, agreements or instruments, (b) violations of statutes,
rules, regulations or court or governmental orders, or (c) failures to
obtain required consents, approvals or authorizations from, or make required
registrations, declarations or filings with, governmental
authorities.
We hereby
consent to the filing of this opinion as an exhibit to the Abbreviated
Registration Statement and to the use of our name in the Prospectus forming a
part of the Registration Statement and the Abbreviated Registration Statement
under the caption “Legal Matters.” In giving this consent, we do not admit that
we are within the category of persons whose consent is required under
Section 7 of the Securities Act and the rules and regulations
thereunder.
Very
truly yours,
|
|
/s/
Maslon Edelman Borman & Brand,
LLP
|
Unassociated Document
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
As
independent registered public accountants, we hereby consent to the use of the
report of Vitale, Caturano & Company, P.C. (whose name has been changed
to Caturano and Company, P.C. effective May 1, 2009) dated March 16,
2009 relating to the financial statements of ZIOPHARM Oncology, Inc. as of
December 31, 2008 and 2007, and for each of the three years in the three-year
period ended December 31, 2008 and from September 9, 2003 (date of inception)
through December 31, 2008 (which report expresses an unqualified
opinion), and to all references to our Firm included in or made a part of
this Registration Statement on Form S-3.
Caturano
and Company, P.C.
December
6, 2009